Electrocardiographic profile of adenosine pharmacological stress testing

HAO SUN\(^1\), YUEQIN TIAN\(^2\), LIHUI ZHENG\(^3\), QINGRONG PAN\(^4\) and BOQIA XIE\(^1\)

\(^1\)Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020; Departments of \(^2\)Nuclear Medicine and \(^3\)Electrophysiology, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037; \(^4\)Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China

Received June 22, 2014; Accepted January 26, 2015

DOI: 10.3892/etm.2015.2279

Abstract. Adenosine stress testing in conjunction with radionuclide myocardial perfusion imaging has become a common approach for the detection of coronary artery disease in patients who are unable to perform adequate levels of exercise. However, specific electrocardiographic alterations during the test have been rarely described. Using a Chinese population, the aim of the present study was to provide a detailed electrocardiographic profile of adenosine stress testing. The study population included 1,168 consecutive outpatients who had undergone adenosine-induced stress myocardial perfusion imaging. Electrocardiographic data during and immediately following the adenosine infusion were collected, and the corresponding myocardial perfusion images were assessed. During adenosine infusion, 174 transient and 47 persistent arrhythmic events occurred in 110 patients (9.42%). Furthermore, frequent premature atrial contractions occurred in 65 individuals and frequent premature ventricular contractions were observed in 73 individuals. Atrioventricular block (AVB) occurred in 75 patients [first degree (I\(^\circ\)) AVB, 16; second degree (II\(^\circ\)) AVB, 58; third degree AVB, 1], while sinoatrial block occurred in eight patients. ST depression emerged in 69 patients. Patients with a baseline I\(^\circ\) AVB had an increased risk of a II\(^\circ\) AVB, and patients exhibiting baseline ST depression were more likely to have a further depressed ST segment during the stress test (odds ratio, 28.68 and 5.01, respectively; both P<0.001). Following adenosine infusion, 10 patients (0.86%) exhibited newly occurred arrhythmic events. However, no patient presented with acute myocardial infarction or sudden mortality. In conclusion, the results demonstrated that adenosine infusion was a safe method, despite the relatively high incidence of arrhythmic events. The majority of arrhythmias that occurred during infusion were transient, were reversible with the termination of infusion and did not indicate abnormal perfusion results.

Introduction

Pharmacological stress testing in conjunction with radionuclide myocardial perfusion imaging has been used as an alternative to dynamic exercise testing for the detection of coronary artery disease and risk stratification in patients who are unable to perform adequate levels of exercise (1-3). Adenosine is the most widely used agent due to its rapid onset of action and short half-life (<10 sec), which allows for dose titration. However, a number of side effects are frequently observed following the intravenous infusion of adenosine. In addition to flushing, nausea and dyspnea, arrhythmia is the most common side effect due to the negative chronotropic effect of adenosine (4-7). Although previous studies have demonstrated the overall safety of adenosine stress testing (8,9), specific electrocardiographic alterations during the process have been rarely described. In addition, whether the newly occurred arrhythmic events are within safe limits or whether they are indications of ischemia or/and are life-threatening is yet to be investigated. Moreover, whether adenosine infusion should be suspended upon the occurrence of severe arrhythmic events, including second degree (II\(^\circ\)) and third degree (III\(^\circ\)) atrioventricular block (AVB) or sinoatrial block (SAB), remains controversial. Shortage of the aforementioned information has impeded the wide application of adenosine stress testing since the method became available in 2003 in China (2,10). Therefore, the aim of the present study was to reveal the detailed characteristics of the electrocardiographic changes during an adenosine stress test, and to investigate the correlation between arrhythmia and perfusion results, in order to provide safety profiles of adenosine stress testing based on a Chinese population.

Materials and methods

Study population. Between May 2010 and January 2012, outpatients with potential diagnoses of coronary artery disease, who had undergone adenosine-induced stress using Technetium-99m sestamibi (99mTc-MIBI) single photon

Correspondence to: Dr Boqia Xie, Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, 8th Gongtinanlu Road, Chaoyang, Beijing 100020, P.R. China

E-mail: dr.boqiaxie@hotmail.com

Key words: adenosine, myocardial perfusion imaging, electrocardiography, arrhythmia, Chinese population
emission computed tomography (SPECT) myocardial perfusion imaging at Fuwai Hospital (Beijing, China), were prospectively enrolled in the study. The contraindications for adenosine stress testing included the occurrence of myocardial infarction within two months, unstable angina, hypotension (systolic blood pressure of <90 mmHg), hypertension (systolic or diastolic blood pressure of >200 or >110 mmHg, respectively), New York Heart Association (11) class IV congestive heart failure, an AVB greater than first degree (I’), patients with a pacemaker implantation or those with asthma or obstructive lung diseases. Ethical approval was obtained from the Ethics Review Board of Fuwai Hospital, and written informed consent was obtained from all the subjects enrolled.

Adenosine infusion protocol. Adenosine (Shenyang Guangda Pharmaceuticals Co., Ltd., Shenyang, China) was infused at a constant rate of 140 µg/kg/min through a peripheral venous catheter, using an accurate computerized infusion pump (BYZ-810; Changsha BEYOND Medical Devices Co., Ltd., Changsha, China) over 6 min (total dose, 0.8 mg/kg body weight). At the third minute of adenosine infusion, 925 MBq 99mTc-MIBI (Radiation Chemistry Department, Beijing Normal University, Beijing, China) was injected as a bolus through the contralateral cubical vein and the adenosine infusion was continued for an additional 3 min. The heart rate and a 12-lead electrocardiogram (ECG) were recorded continuously at the baseline (at least 2 min prior to the infusion), during infusion and for at least 3 min after the termination of infusion. ECG data were analyzed by an experienced electrophysiologist, according to the 2008 AHA/ACC/HR’S recommendations for the standardization and interpretation of the ECG (12-14). The electrophysiologist was blinded to the myocardial perfusion results. Systolic and diastolic blood pressure were monitored every minute during the entire process. The administration of adenosine was terminated under the following circumstances: Patients with poorly tolerated side effects; severe hypotension (systolic blood pressure of <80 mmHg); horizontal or downsloping ST depression of >0.1 mV; ST elevation of >0.1 mV; crescendo II’ or III’ AVB or SAB.

SPECT acquisition protocol. 99mTc-MIBI SPECT myocardial perfusion imaging was performed 1.0–1.5 h after the completion of adenosine infusion using a dual-head gamma camera equipped with low-energy, high-resolution collimators (e.cam; Siemens Medical Solutions USA, Inc., Malvern, PA, USA). Projection data were acquired from 16 views over 180˚ from 45˚ right anterior oblique to 45˚ left anterior oblique, with 25 sec per view, on a 64x64 matrix. The image slices were analyzed visually by two experienced nuclear cardiologists in consensus based on 17 segments. Rest images were obtained the following day if the stress images were abnormal. The final perfusion results were determined by comparing the stressed images with the rest images. Reversible and irreversible defects were defined as ischemia and infarction, respectively, and if both patterns existed, the condition was defined as ischemia combined with infarction.

Statistical analysis. Statistical analysis was performed using SPSS 19.0 software (IBM, Armonk, NY, USA). Continuous variables are expressed as the mean ± standard deviation, while categorical variables are presented as frequencies. The Student’s t-test was used to compare the differences in continuous variables, while the χ² test was used to analyze the categorical variables. Logistic regression analysis was used to determine the risk factors. P<0.05 was considered to indicate a statistically significant difference.

Results

Patient characteristics. A total of 1,168 patients (male, 420; female, 748; mean age, 58±10 years) were enrolled in the study. Of these individuals, 330 patients had type 2 diabetes mellitus, 230 patients had hypertension and seven patients had undergone a previous percutaneous coronary intervention (Table I).

Effects of adenosine infusion on hemodynamic parameters and cardiac electrical conduction. Blood pressure, heart rate and electrocardiographic intervals at the baseline, at the maximal response during adenosine infusion and at 2 min after the completion of adenosine administration are summarized in Table II. The intravenous adenosine infusion was demonstrated to induce a significant decrease in systolic blood pressure and an increase in the heart rate. In addition, adenosine infusion caused a prolongation of the PQ interval, without affecting the QRS interval. However, considering that an inverse ratio exists between an increasing heart rate and the shortening of the QT interval (15), the shortening of the QT interval may be caused by the increased heart rate rather than the infusion of adenosine. The maximal changes in the hemodynamic parameters and cardiac electrical conduction appeared between 2 and 3 min after the initiation of adenosine infusion. The parameters returned to the baseline level at 2 min after the termination of infusion.

Baseline ECG characteristics. Baseline ECG characteristics are summarized in Table III. In total, 357 baseline arrhythmic events were observed in 340 patients (29.11%). A total of 73 patients (6.25%) exhibited sinus bradycardia (heart rate of <60 bpm), while 38 patients (3.25%) presented with sinus tachycardia (heart rate of >100 bpm). In addition, 74 patients (6.34%) had premature atrial contractions (>6 bpm) and 69 patients (5.91%) had premature ventricular contractions (>6 bpm). A I’ AVB was identified in 22 patients (1.88%),
and 41 patients (3.51%) exhibited atrial fibrillation. A total of 32 patients (2.74%) presented with a right bundle branch block, while eight patients (0.68%) exhibited a left bundle branch block. Furthermore, 96 patients (8.22%) exhibited baseline ST depression (>0.1 mV).

Figure 1. Emerging time of newly occurred arrhythmias during adenosine infusion. The majority of arrhythmic events emerged within the 2-3 min interval after adenosine infusion. PAC, premature atrial contractions; PVC, premature ventricular contractions; AVB, atrioventricular block; SAB, sinoatrial block; I˚, first degree; II˚, second degree; III˚, third degree.

Table II. Effects of the adenosine stress test on hemodynamic parameters and cardiac electrical conduction.

| Parameter                      | Baseline     | Peak effect  | 2 min after the termination of adenosine infusion |
|--------------------------------|--------------|--------------|--------------------------------------------------|
| HR (bpm)                       | 76±14        | 91±16a       | 83±15b                                           |
| SBP (mmHg)                     | 131±20       | 109±19b      | 115±19a                                          |
| DBP (mmHg)                     | 80±12        | 68±12b       | 74±12b                                           |
| PQ interval (msec)             | 153±21       | 166±22a      | 154±20b                                          |
| QRS interval (msec)            | 84±11        | 85±10        | 85±11b                                           |
| QT interval (msec)             | 375±31       | 365±33a      | 373±31b                                          |

*a*<0.05 and *b*>0.05, vs. baseline condition (paired t-test). HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table III. Baseline ECG characteristics.

| Arrhythmia         | Cases, n (%) |
|--------------------|--------------|
| Sinus bradycardia  | 73 (6.25)    |
| Sinus tachycardia  | 38 (3.25)    |
| Frequent PAC       | 74 (6.34)    |
| Frequent PVC       | 69 (5.91)    |
| Atrial fibrillation| 41 (3.51)    |
| I˚ AVB             | 22 (1.88)    |
| RBBB               | 32 (2.74)    |
| LBBB               | 8 (0.68)     |
| ST depression      | 96 (8.22)    |

ECG, electrocardiogram; PAC, premature atrial contractions; PVC, premature ventricular contractions; AVB, atrioventricular block; I˚, first degree; RBBB, right bundle branch block; LBBB, left bundle branch block. Furthermore, 96 patients (8.22%) exhibited baseline ST depression (>0.1 mV).

**ECG alterations during adenosine infusion.** Newly occurred arrhythmias during adenosine infusion are summarized in Table IV and Fig. 1. During adenosine infusion, 221 arrhythmic events occurred in 110 patients (9.42%), among which 65 individuals (5.6%) had frequent premature atrial contractions and 73 patients (6.3%) exhibited frequent premature ventricular contractions. In total, 16 patients (1.4%) had I˚ AVB, 58 patients (5.0%) had II˚ AVB and one individual (0.09%) developed III˚ AVB following the development of II˚ AVB. In addition, eight individuals (0.68%) exhibited SAB. Of these arrhythmic events, 174 (14.90%) were transient (lasted for <10 sec), 34 (2.91%) were persistent (lasted for ≥10 sec) but self-terminated and 13 events (1.11%) were persistent and diminished following the termination of adenosine infusion. Early dose-termination was carried out in 15 patients. The newly occurred severe arrhythmias (SAB and II˚ or III˚ AVB) emerged when the infusion initiated and reached the maximal point during the 2-3 min interval following infusion (Fig. 1). The mean effective systolic blood pressure at the 2-3 min interval was 103±22 mmHg (baseline...
systolic blood pressure, 129±20 mmHg), which was considered to be a tolerable level.

Of the 1,168 patients, newly occurred ST depression (>0.1 mV) was observed in 69 patients (5.91%). During the adenosine stress test, no patient presented with acute myocardial infarction or sudden mortality, and no patient required specific treatment.

With regard to the correlations between the gender, age and baseline ECG characteristics of the patients and the development of II˚ A VB during adenosine infusion, only the baseline I˚ A VB was determined to be a predictor [P<0.001; odds ratio (OR), 28.68; 95% confidence interval (CI), 8.81-93.31; Table V). Furthermore, patients with a baseline ST depression were more likely to have a further depressed ST segment during the adenosine stress test (P<0.001; OR, 5.01; 95% CI, 2.76-9.10), possibly due to the already existing hypoperfusion prior to the test (Table VI).

**Table IV. Occurrence of new arrhythmic events during adenosine infusion.**

| Arrhythmia       | Total (n) | Cases (n) | Emerging time (sec) | Cases (n) | Emerging time (sec) | Duration (sec) | Self termination (n) | Early termination (n) |
|------------------|-----------|-----------|---------------------|-----------|---------------------|----------------|----------------------|----------------------|
| Frequent PAC     | 65        | 58        | 112±76              | 7         | 96±42               | 169±97         | 5                    | 0                    |
| Frequent PVC     | 73        | 57        | 127±69              | 16        | 109±72              | 173±85         | 8                    | 3                    |
| I˚ AVB           | 16        | 0         | -                   | 16        | 138±57              | 114±70         | 16                   | 2                    |
| II˚ AVB          | 58        | 51        | 179±78              | 7         | 171±69              | 57±42          | 5                    | 9                    |
| III˚ AVB         | 1         | 0         | -                   | 1         | 77                  | 48             | 0                    | 1                    |
| SAB              | 8         | 8         | 147±90              | 0         | -                   | -              | -                    | -                    |
| Total            | 221       | 174       | 47                  | 47        |                     | 15             |                      |                      |

**Table V. Logistic regression analysis for the development of II˚ AVB during adenosine infusion.**

| Variables        | OR    | 95% CI      | P-value |
|------------------|-------|-------------|---------|
| Gender           | 1.09  | 0.61-1.95   | 0.77    |
| Age              | 1.00  | 0.97-1.03   | 0.88    |
| Baseline ST depression | 0.00  | 0.00       | 1.00    |
| Baseline sinus tachycardia | 0.00  | 0.00       | 1.00    |
| Baseline sinus bradycardia | 0.38  | 0.10-1.46  | 0.16    |
| Baseline I˚ AVB  | 28.68 | 8.81-93.31  | 0.001   |
| Baseline RBBB    | 0.17  | 0.02-1.61   | 0.12    |
| Baseline LBBB    | 0.45  | 0.03-6.16   | 0.55    |
| Baseline PVC     | 0.57  | 0.13-2.41   | 0.44    |
| Baseline PAC     | 0.53  | 0.12-2.29   | 0.40    |
| Baseline atrial fibrillation | 0.00  | 0.00       | 1.00    |

**Table VI. Logistic regression analysis for the development of ST depression during adenosine infusion.**

| Variables        | OR    | 95% CI      | P-value |
|------------------|-------|-------------|---------|
| Gender           | 0.95  | 0.55-1.62   | 0.84    |
| Age              | 0.99  | 0.96-1.01   | 0.36    |
| Baseline ST depression | 5.01  | 2.76-9.10  | 0.001   |
| Baseline sinus tachycardia | 0.67  | 0.15-2.97  | 0.60    |
| Baseline sinus bradycardia | 0.76  | 0.26-2.27  | 0.63    |
| Baseline I˚ AVB  | 5.01  | 2.76-9.10   | 0.001   |
| Baseline RBBB    | 0.82  | 0.11-6.28   | 0.85    |
| Baseline LBBB    | 0.00  | 0.00       | 1.00    |
| Baseline PVC     | 0.92  | 0.32-2.71   | 0.88    |
| Baseline PAC     | 1.14  | 0.42-3.05   | 0.80    |
| Baseline atrial fibrillation | 0.58  | 0.13-2.65  | 0.48    |
| Baseline atrial fibrillation | 0.58  | 0.13-2.65  | 0.48    |
| Newly occurred II˚ AVB | 0.40  | 0.05-2.94  | 0.37    |
| Newly occurred I˚ AVB | 1.58  | 0.20-12.4  | 0.67    |
| Persistent PVC   | 1.56  | 0.20-12.32  | 0.67    |
| Persistent PAC   | 0.00  | 0.00       | 1.00    |
| Newly occurred SAB | 0.00  | 0.00       | 1.00    |

OR, odds ratio; CI, confidence interval; AVB, atrioventricular block; I˚, first degree; II˚, second degree; III˚, third degree; SAB, sinoatrial block.
episodes were transient in nine patients; however, one patient had persistent SAB and ischemic ST changes due to coronary spasm, which was revealed by an immediate coronary angiogram.

Myocardial perfusion imaging results. Perfusion imaging revealed ischemia in 79 patients (6.76%), infarction in 10 patients (0.86%) and ischemia combined with infarction in seven patients (0.60%). Logistic regression analysis demonstrated that male patients and those who had newly occurred ST depression during adenosine infusion had an increased risk of abnormal perfusion results (OR, 2.14 and 95% CI, 1.35-3.40; OR, 14.66 and 95% CI, 8.12-26.48, respectively; both P<0.01; Table VIII).

Discussion

In the present study, the detailed electrocardiographic changes through the entire process of the adenosine stress test were described. Adenosine was shown to have a strong depressant effect on the atrioventricular conduction system; however, an insignificant influence was observed on ventricular depolarization and repolarization. The newly occurred severe arrhythmias tended to emerge during the 2-3 min interval following adenosine administration, after which they gradually decreased. The majority of the newly occurred arrhythmias were transient and required no special treatment. In addition, no statistical correlation was observed between the newly occurred arrhythmias and abnormal perfusion results.

Adenosine is an autacoid that plays a critical role in regulating cardiac function. There are at least four subtypes of adenosine receptors, known as A1, A2A, A2B and A3, of which A2A is the predominant subtype responsible for coronary blood flow regulation (4). Documented studies

### Table VII. Occurrence of arrhythmias following the termination of adenosine infusion.

| Patient number | Gender | Age (years) | Baseline arrhythmia | Arrhythmia during infusion | Arrhythmia after infusion | Onset time (sec) | Arrhythmia duration (sec) | Treatment |
|----------------|--------|-------------|---------------------|---------------------------|--------------------------|------------------|--------------------------|-----------|
| 79             | F      | 41          | None                | None                      | SAB                      | 311              | 12                       | PCI       |
| 248            | F      | 50          | Sinus bradycardia   | II' AVB                   | SAB                      | 27               | 9                        | None      |
| 672            | F      | 59          | None                | None                      | II' AVB                  | 49               | 3                        | None      |
| 762            | F      | 62          | None                | None                      | SAB                      | 145              | 2                        | None      |
| 773            | F      | 62          | Sinus bradycardia   | None                      | SAB                      | 120              | 2                        | None      |
| 851            | F      | 65          | None                | None                      | II' AVB                  | 12               | 8                        | None      |
| 925            | M      | 67          | None                | None                      | II' AVB                  | 12               | 2                        | None      |
| 984            | F      | 69          | None                | None                      | II' AVB                  | 38               | 3                        | None      |
| 1063           | F      | 72          | I' AVB              | None                      | II'+III' AVB             | 64               | 7                        | None      |
| 1108           | F      | 74          | Sinus tachycardia   | None                      | SAB                      | 125              | 3                        | None      |

*Time following the initiation of infusion. PCI, percutaneous coronary intervention; AVB, atrioventricular block; I', first degree; II', second degree; III', third degree; SAB, sinoatrial block; F, female; M, male.

### Table VIII. Logistic regression analysis for the occurrence of abnormal myocardial perfusion results.

| Variables                                 | OR     | 95% CI          | P-value |
|-------------------------------------------|--------|-----------------|---------|
| Gender                                    | 2.14   | 1.35-3.40       | 0.001   |
| Age                                       | 1.02   | 1.00-1.04       | 0.12    |
| Baseline ST depression                    | 0.74   | 0.33-1.63       | 0.45    |
| Baseline sinus tachycardia                | 1.03   | 0.27-3.94       | 0.96    |
| Baseline sinus bradycardia                | 1.36   | 0.57-3.22       | 0.49    |
| Baseline I' AVB                           | 1.03   | 0.20-5.22       | 0.97    |
| Baseline RBBB                             | 1.65   | 0.50-5.43       | 0.41    |
| Baseline LBBB                             | 0.00   | 0.00            | 1.00    |
| Baseline PVC                              | 1.00   | 0.39-2.56       | 1.00    |
| Baseline PAC                              | 1.12   | 0.47-2.69       | 0.80    |
| Baseline atrial fibrillation              | 0.45   | 0.10-2.03       | 0.30    |
| Newly occurred ST depression              | 14.66  | 8.12-26.48      | 0.001   |
| Newly occurred II'AVB                     | 1.00   | 0.33-3.05       | 1.00    |
| Newly occurred I'AVB                      | 0.83   | 0.09-7.33       | 0.86    |
| Persistent PVC                            | 0.00   | 0.00            | 1.00    |
| Persistent PAC                            | 0.00   | 0.00            | 1.00    |
| Newly occurred SAB                        | 0.00   | 0.00            | 1.00    |
| Arrhythmia occurrence after adenosine infusion | 1.96  | 0.24-16.36      | 0.53    |

OR, odds ratio; CI, confidence interval; AVB, atrioventricular block; I', first degree; II', second degree; RBBB, right bundle branch block; LBBB, left bundle branch block; SAB, sinoatrial block; PVC, premature ventricular contractions; PAC, premature atrial contractions.
have confirmed that adenosine-induced stress myocardial perfusion imaging has a relatively high sensitivity and specificity for the detection of coronary artery disease (1,2). Furthermore, this method offers a number of advantages when compared with the exercise test, including a rapid onset of action, a direct coronary vasodilatory effect, timely dose adjustment for its short half-life (<10 sec), a more standard operational procedure and a procedure that is less influenced by drugs (3). However, the unselected activation of adenosine receptors may lead to various undesirable side effects, among which ECG alterations are the most common due to the negative chronotropic effect of the A1 receptor, which suppresses the activity of the sinus node, atrioventricular junction and His-Purkinje system (4-7).

In the present study, the incidence of newly occurred AVB events was 6.42%, which is comparable with US population (7.63%) (8) and Japanese population (4.57%) (9) studies. Age was not found to be a predictor of the development of severe arrhythmia, indicating that adenosine may also be safe for elder Chinese patients. However, attention should be paid for patients with a baseline I’ AVB, as these individuals were more likely to develop a II’ AVB during adenosine infusion. Previous studies have demonstrated that new occurrence of ST depression during adenosine infusion is an independent predictor of future cardiac events (16-18). Consistently, in the present study, patients with newly developed ST depression were more likely to have normal perfusion results. Thus, attention should also be paid when ischemic ST changes emerge during adenosine infusion.

Finally, although the incidence is low (19-21), a coronary spasm may occur during or after the adenosine infusion. This may be due to the activation of the A1 receptor, which induces the contraction of vascular smooth muscle (22,23). In addition, delayed coronary spasms that occur at the termination of adenosine infusion may be the result of the withdrawal of vasodilatory effects and the reflected onset of vascular smooth muscle contraction (21). Therefore, intensive monitoring is highly recommended even following adenosine infusion.

The current preliminary study has a number of inherent limitations due to its single-centered research nature. In addition, the sample size was relatively small, which may lead to selection bias. Therefore, a randomized multicentered trial that includes a greater number of patients is required to confirm the ECG profiles of adenosine stress testing in a Chinese population.

In conclusion, based on a Chinese population, the findings of the present prospective study indicate the safety of adenosine pharmacological hyperemia in conjunction with radionuclide perfusion imaging. Despite the relative high incidence of arrhythmic events, the majority of arrhythmias that occurred during adenosine infusion were transient and did not indicate abnormal perfusion results.

Acknowledgements

The study was supported by grants from the Young Scholar Funding of Chaoyang Hospital (no. 2014-YQ-01) and the National Natural Science Foundation of China (nos. 81400268 and 81100587).

References

1. Verani MS, Mahmarian JJ, Hixson JB, et al: Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise. Circulation 82: 80-87, 1990.
2. Tian YQ, Wang JC, He ZH, et al: Diagnostic value of adenosine $(99m)$Tc-MIBI myocardial perfusion imaging for detecting coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi 33: 58-61, 2005 (In Chinese).
3. Gupta NC, Esterbrooks DJ, Hillelman DE and Mohiuddin SM: Comparison of adenosine and exercise thallium-201 single-photon emission computed tomography (SPECT) myocardial perfusion imaging. The GE SPECT Multicenter Adenose Study Group. J Am Coll Cardiol 19: 248-257, 1992.
4. Mustafa SJ, Morrison RR, Teng B and Pelleg A: Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol 193: 161-188, 2009.
5. Alkoutami GS, Reeves WC and Movahed A: The safety of adenosine pharmacologic stress testing in patients with first-degree atrioventricular block in the presence and absence of atrioventricular blocking medications. J Nucl Cardiol 6: 495-497, 1999.
6. Verani MS: Pharmacological stress with adenosine for myocardial perfusion imaging. Semin Nucl Med 21: 266-272, 1991.
7. Alkoutami GS, Reeves WC and Movahed A: The frequency of atrioventricular block during adenosine stress testing in young, middle-aged, young-old, and old-old adults. Am J Geriatr Cardiol 10: 199-210, 2001.
8. Cerqueira MD, Verani MS, Schweiger M, et al: Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 23: 384-389, 1994.
9. Hatanaka K, Doi M, Hirohata S, et al: Safety of and tolerance to adenosine infusion for myocardial perfusion single-photon emission computed tomography in a Japanese population. Circ J 71: 904-910, 2007.
10. Fan ZJ, Chen LB, Li F, et al: The application of adenosine stress myocardial perfusion tomographic imaging in detecting coronary artery disease. Zhonghua Nei Ke Za Zhi 45: 112-115, 2006 (In Chinese).
11. The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Dolgin M (ed.). 9th edition. Little, Brown & Co., Boston, USA, pp253-256, 1994.
12. Surawicz B, Childers R, Deal BJ, et al: American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society: AHA/ACC/HR Society recommendations for the standardization and interpretation of the electrocardiogram: part III: atrioventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 55: 976-981, 2005.
13. Rautaharju PM, Surawicz B, Gettes LS, et al; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society: AHA/ACC/HR Society recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 53: 982-991, 2009.
14. Wagner GS, Macfarlane P, Wellens H, et al; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society: AHA/ACC/HR Society recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 53: 1003-1011, 2009.
15. Kligfield P, Lax KG and Okin PM: QT interval-heart rate relation during exercise in normal men and women: definition by linear regression analysis. J Am Coll Cardiol 28: 1547-1555, 1996.

16. Marshall ES, Raichlen JS, Kim SM, Intenzo CM, Sawyer DT, Brody EA, et al: Prognostic significance of ST-segment depression during adenosine perfusion imaging. Am Heart J 130: 58-66, 1995.

17. Klodas E, Miller TD, Christian TF, Hodge DO and Gibbons RJ: Prognostic significance of ischemic electrocardiographic changes during vasodilator stress testing in patients with normal SPECT images. J Nucl Cardiol 10: 4-8, 2003.

18. Abbott BG, Afshar M, Berger AK and Wackers FJ: Prognostic significance of ischemic electrocardiographic changes during adenosine infusion in patients with normal myocardial perfusion imaging. J Nucl Cardiol 10: 9-16, 2003.

19. Golzar J, Mustafa SJ and Movahed A: Chest pain and ST-segment elevation 3 minutes after completion of adenosine pharmacologic stress testing. J Nucl Cardiol 11: 744-746, 2004.

20. Stern S and Bayes de Luna A: Coronary artery spasm: a 2009 update. Circulation 119: 2531-2534, 2009.

21. Rosenberg T and Perdrisot R: Coronary spasm after an adenosine stress test: an adverse effect of a vasodilator. Acta Cardiol 63: 401-404, 2008.

22. Ansari HR, Teng B, Nadeem A, Roush KP, Martin KH, Schnerrmann J and Mustafa SJ: A(1) adenosine receptor-mediated PKC and p42/p44 MAPK signaling in mouse coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol 297: H1032-H1039, 2009.

23. Sato A, Terata K, Miura H, Toyama K, Loberiza FR Jr, Hatoum OA, et al: Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am J Physiol Heart Circ Physiol 288: H1633-H1640, 2005.